Skip to content

Journal of Pharmaceutical Sciences

ISSN 0022-3549

11 papers in the library · 141 citations · publishing 1975-2018

Papers

Sort Most recent Most cited

Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach.

Journal of Pharmaceutical Sciences February 2018 Rakesh Awasthi, Guohua An, Maureen D Donovan et al.

The medical use of marijuana is increasing, yet little is known about the exposure-response relationship for its psychoactive effects. It is well known that the plasma concentrations of the principal psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), do not directly correlate to the observed psychoactive effects. The purpose of this research was to use an effect-compartment...

DOI: 10.1016/j.xphs.2017.09.009 (opens in new tab) Full text (opens in new tab) Clinical pharmacokinetics Metabolism Metabolite kinetics Pharmacokinetic/pharmacodynamic models +2

Microdosing: A Critical Assessment of Human Data

Journal of Pharmaceutical Sciences August 23, 2012 Malcolm Rowland 51 citations

Ultrasensitive analytical methodologies have now made possible the ability to characterize the pharmacokinetics (PK) of compounds following administration to humans of a minute, subpharmacologic dose, a microdose. This has the potential to provide pre-IND information to help in early candidate selection, but only if such information is reasonably predictive of PK at pharmacologic doses. The...

DOI: 10.1002/jps.23290 (opens in new tab) Microdose Drug development Pharmacology Pharmacokinetics +1

Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier.

Journal of Pharmaceutical Sciences December 1, 2009 Nicolas Tournier, Pascal André, Sandy Blondeel et al. 14 citations

The (99m)Tc-tricarbonyl core may be used as an ideal tool for gamma-labeling ligands in noninvasive SPECT imaging. However, most (99m)Tc-tricarbonyl-labeled agents have difficulty crossing the blood-brain barrier (BBB). We radiolabeled the neuroactive indole ibogaine with (99m)Tc-tricarbonyl and measured its transport into the mouse brain by in situ brain perfusion. We measured the interactions...

DOI: 10.1002/jps.21771 (opens in new tab) Full text (opens in new tab) Brain imaging Neuroimaging Molecular imaging Imaging agents +23

Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat.

Journal of Pharmaceutical Sciences April 2008 Vijay Upreti, Natalie D. Eddington

Fluoxetine has been shown to provide protection from MDMA induced long term neurotoxicity. The purpose of this investigation is to evaluate the pharmacokinetic drug interaction between MDMA and fluoxetine and also to determine the role of P-glycoprotein (P-gp) on mediating drug-drug interactions with MDMA. Bi-directional transport studies were conducted across MDCK-MDR1 and Caco-2 monolayers....

Synthesis and Action on the Central Nervous System of Mescaline Analogues Containing Piperazine or Homopiperazine Rings

Journal of Pharmaceutical Sciences March 1, 1983 Michal W. Majchrzak, A Kotełko, Roman Guryn et al. 5 citations

Structural juxtaposition of the 3,4,5-trimethoxyphenyl group in the same molecule with a piperazine or homopiperazine ring has been realized in a series of mescaline analogues (I-IV) as part of an investigation into the pharmacological properties of the seven-membered perhydro-1,4-diazepines (homopiperazines). The analogous six-membered piperazines were synthesized and tested as reference...

DOI: 10.1002/jps.2600720324 (opens in new tab) Mescaline Piperazine Action physics Central nervous system +5

Molecular Connectivity Analysis of Hallucinogenic Mescaline Analogs

Journal of Pharmaceutical Sciences July 1, 1979 Richard A Glennon, Lemont B. Kier, Alexander T. Shulgin 29 citations

The hallucinogenic (psychotomimetic) potency of 10 mescaline analogs was examined by molecular connectivity analysis. Potencies could be described by a two-term relating equation, which explained 94% of the variance in activity, on the basis of structural variation, 2,5-Dimethoxy substitution as well as the nature of the 4-position substituent played an important role in determining...

DOI: 10.1002/jps.2600680733 (opens in new tab) Mescaline Psychotomimetic Hallucinogen Potency +3

Actions of Mescaline on Isolated Rat Atria

Journal of Pharmaceutical Sciences July 1, 1977 Peter K. S. Siegl, Raymond F. Orzechowski 2 citations

Mescaline, in concentrations of 5 x 10(-4) and 1 x 10(-3) M, produced negative chronotropic and positive inotropic responses in isolated, spontaneously beating rat atria. In tissues driven at a constant rate, the inotropic response was diminished greatly, indicating that the increment in the force of contraction was secondary to the reduction in rate. These chronotropic and inotropic responses...

DOI: 10.1002/jps.2600660708 (opens in new tab) Mescaline Chronotropic Inotrope Metiamide +10

GLC-Mass Spectral Analysis of Psilocin and Psilocybin

Journal of Pharmaceutical Sciences May 1, 1977 David B. Repke, Dale Thomas Leslie, Daniel Mandell et al. 31 citations

With the combined technique of GLC-mass spectrometry, psilocin and psilocybin, two hallucinogenic indoles, were analyzed as their trimethylsilyl derivatives. The method was applied to these two components in an extract of Psilocybe cubensis (Earle) Sing.

DOI: 10.1002/jps.2600660539 (opens in new tab) Psilocybin Hallucinogen Mass spectrometry Spectral analysis +3

Baeocystin in Psilocybe semilanceata.

Journal of Pharmaceutical Sciences January 1977 D B Repke, D T Leslie

Baeocystin and psilocybin were found in extracts of a variety of Psilocybe semilanceata. Psilocybin (but not baeocystin) was also detected in extracts of a related species. Psilocyte pelliculosa. Traces of psilocin were present in these two species. The structures of the isolated compounds were corroborated using mass spectrometry and UV spectroscopy.

Synthesis of Potential Mescaline Antagonists

Journal of Pharmaceutical Sciences October 1, 1976 F. Jun. Desantis, Karl A. Nieforth 4 citations

1-[2-(3,4,5-Trimethoxyphenyl)ethyl]-3-pyrroline, 2-(3,4,5-trimethoxybenzyl)-1,2,3,6-tetrahydropyridine, N-n-propylmescaline, N-cyclopropylmethylmescaline, and N-allylmescaline were synthesized as potential mescaline antagonists. The ability of these compounds to antagonize mescaline-induced disruption of swim behavior is also given.